SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd is rallying behind Crow With Knife ($CAW), a multi-chain meme coin, particularly on the Cronos chain, with community members highlighting its organic growth, fully circulated supply, and deflationary mechanisms. The community is focused on its presence across multiple chains like Solana, Ethereum, and Cronos, and its unique burn mechanism.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TREASURE GLOBAL INC is trending due to a potential short squeeze, with community members citing a high borrow rate and unavailable short inventory as catalysts. Discussions highlight the stock's momentum and comparisons to similar plays like $SMX and $CETX, with some anticipating a significant price increase. Community members are focused on the low float and potential for further upward movement.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to its recent explosive surge, driven by interest in its traceability technology and potential short squeeze, mirroring setups seen in other low-float runners. Community discussions revolve around its high short interest and the possibility of further upward momentum, while also identifying similar setups in other micro-cap stocks. Traders are closely watching for continued volatility and potential profit-taking opportunities, as well as the company's future plans and partnerships.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as a low-float play, with traders actively discussing its potential for a squeeze similar to $CETX and $SMX. Community members are focused on its small float and high short interest, speculating on a possible breakout. Some caution is advised due to past ghosting behavior.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian ($RIVN) is trending amid discussions of an upcoming AI Autonomy Day, with the community anticipating potential advancements. A recent downgrade from Morgan Stanley is also a hot topic, with many investors dismissing its impact. Despite mixed reviews on reliability, customer satisfaction remains high, fueling optimism about the company's long-term potential in the EV market.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

BDRX is trending due to its recent progress in the Phase 3 Serenta trial, specifically the approval of the CTA in Europe, which has sparked significant interest in the stock's potential. The community is actively discussing the low float and potential for a squeeze, while also considering the company's market cap and upcoming data releases. Some traders are also discussing reverse split implications.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to traders targeting low float stocks, drawing comparisons to previous runners like $SMX and $TGL. Community members are discussing entry points and anticipating a breakout, while others urge caution, citing the stock's history and volatility. The stock's projected profit growth for 2025 appears to be fueling some of the bullish sentiment.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending amid discussions of a potential short squeeze, drawing comparisons to recent explosive moves in other low-float stocks like $SMX. Community members are actively debating its potential, with some pointing to the company's real estate holdings and others highlighting the risks of dilution. The stock's high volatility and significant trading volume are contributing to the heightened interest.

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

MetaVia Inc.

MTVA is trending amid discussions of its low float and potential for a squeeze, with some comparing it to other recent high-flying stocks. Community members are actively watching for price target potential and momentum, while noting the company's reverse stock split and focus on therapies targeting obesity and glucose metabolism.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to a mix of factors, including recent downgrades from Morgan Stanley impacting investor sentiment and discussions around viral reviews highlighting software glitches. The community is debating the company's valuation, potential for a short squeeze, and the impact of Saudi ownership and funding, while also eyeing the upcoming unveiling of a third EV model in 2026.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$APTO Aptose Biosciences reports data from Phase 1/2 TUSCANY trial  
 
Aptose Biosciences reported updated and new data from Aptose&#39;s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia patients dosed with a 40 mg or 80 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine. The TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.  
 
Earlier this year, Aptose announced the initiation of the TUSCANY trial and dosing in newly diagnosed AML patients at an initial dose of 40 mg TUS in the first cohort of four patients. The second cohort of patients is now receiving 80 mg TUS. Data from the first two cohorts, with a 40 mg or 80 mg dose of tuspetinib in the TUS+VEN+AZA combination, reveal promising clinical safety and antileukemic activity. To date, four newly diagnosed AML patients received the initial dose of TUS as part of the combination. Notably, a patient with biallelic TP53 mutations and a complex karyotype and FLT3-wildtype achieved a complete remission (CR) and the clinical site reported no measurable residual disease in this patient.  
 
One FLT3-wildtype patient having an IDH-2 mutation achieved a CR and MRD-negative status. Another FLT3-wildtype patient achieved a CRi during Cycle 1 and MRD-negative status. The first three patients continue on treatment, while a fourth patient did not respond at this 40 mg dose level of TUS and was discontinued. The 40 mg dose of the TUS+VEN+AZA triplet remains safe, and no dose-limiting toxicities have been reported. To date, three newly diagnosed AML patients having diverse mutation profiles have received the 80 mg of TUS, as part of the TUS+VEN+AZA combination. The 80 mg TUS dose has been considered the optimal dose that has demonstrated safety and consistent blood exposure levels that exert potent antileukemic activity.  
 
All patients achieved blast reductions in Cycle 1 that met the criteria for complete remissions and continue on treatment. Notably, another TP53-mutated/CK and FLT3-wildtype patient achieved blast reductions that met CRi criteria in Cycle 1 and is now receiving additional therapy in Cycle 2. The second patient, having FLT3-wildtype status, achieved a CR. The third patient, having FLT3-ITD and NPM1 mutations and entering the trial with a 75% bone marrow blast count, achieved a CRi. All three patients are early in their course of treatment and are expected to show further improvements in their disease status as they are all continuing with treatment, and MRD status will be monitored as the patients move through their courses of therapy.  
 
The 80 mg dose of TUS, as part of the TUS+VEN+AZA triplet, continues to show favorable safety with no dose-limiting toxicities having been reported. &quot;The treatment paradigm for AML is shifting to triplet combination therapy,&quot; said Rafael Bejar, CMO. &quot;We have always maintained that tuspetinib, with its notable safety profile and ability to treat the larger, difficult-to-treat AML populations with high-risk mutations, could be an ideal drug for a triplet combination therapy in the frontline setting. With the majority of patients already achieving complete responses -- including early responses in patients with adverse mutations -- the clinical findings to date are bearing that out.&quot;

perchedcat

Anand Raghavan

StockTwits Web

Aptose Biosciences Inc

 Aptose Biosciences reports data from Phase 1/2 TUSCANY trial  
 
Aptose Biosciences reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia patients dosed with a 40 mg or 80 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine. The TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.  
 
Earlier this year, Aptose announced the initiation of the TUSCANY trial and dosing in newly diagnosed AML patients at an initial dose of 40 mg TUS in the first cohort of four patients. The second cohort of patients is now receiving 80 mg TUS. Data from the first two cohorts, with a 40 mg or 80 mg dose of tuspetinib in the TUS+VEN+AZA combination, reveal promising clinical safety and antileukemic activity. To date, four newly diagnosed AML patients received the initial dose of TUS as part of the combination. Notably, a patient with biallelic TP53 mutations and a complex karyotype and FLT3-wildtype achieved a complete remission (CR) and the clinical site reported no measurable residual disease in this patient.  
 
One FLT3-wildtype patient having an IDH-2 mutation achieved a CR and MRD-negative status. Another FLT3-wildtype patient achieved a CRi during Cycle 1 and MRD-negative status. The first three patients continue on treatment, while a fourth patient did not respond at this 40 mg dose level of TUS and was discontinued. The 40 mg dose of the TUS+VEN+AZA triplet remains safe, and no dose-limiting toxicities have been reported. To date, three newly diagnosed AML patients having diverse mutation profiles have received the 80 mg of TUS, as part of the TUS+VEN+AZA combination. The 80 mg TUS dose has been considered the optimal dose that has demonstrated safety and consistent blood exposure levels that exert potent antileukemic activity.  
 
All patients achieved blast reductions in Cycle 1 that met the criteria for complete remissions and continue on treatment. Notably, another TP53-mutated/CK and FLT3-wildtype patient achieved blast reductions that met CRi criteria in Cycle 1 and is now receiving additional therapy in Cycle 2. The second patient, having FLT3-wildtype status, achieved a CR. The third patient, having FLT3-ITD and NPM1 mutations and entering the trial with a 75% bone marrow blast count, achieved a CRi. All three patients are early in their course of treatment and are expected to show further improvements in their disease status as they are all continuing with treatment, and MRD status will be monitored as the patients move through their courses of therapy.  
 
The 80 mg dose of TUS, as part of the TUS+VEN+AZA triplet, continues to show favorable safety with no dose-limiting toxicities having been reported. "The treatment paradigm for AML is shifting to triplet combination therapy," said Rafael Bejar, CMO. "We have always maintained that tuspetinib, with its notable safety profile and ability to treat the larger, difficult-to-treat AML populations with high-risk mutations, could be an ideal drug for a triplet combination therapy in the frontline setting. With the majority of patients already achieving complete responses -- including early responses in patients with adverse mutations -- the clinical findings to date are bearing that out."